Annual Meeting

Read the Annual Meeting Abstracts

ASGCT Staff - April 27, 2021

Read our collection of the latest gene and cell therapy research ahead of presentation at the 24th Annual Meeting.

We are proud to share our collection of abstracts that will be presented at the 24th Annual Meeting! Read about the most innovative science in the field from more than 800 pieces of research that are now available digitally and as a PDF.

Below you'll find highlights from the research, including the Top Abstracts, which will be presented during the Presidential Symposium on May 13, and the Clinical Trials Spotlight abstracts, which will be presented during the Clinical Trials Spotlight Symposium on May 14.

Read the Digital Abstracts     Download the PDF

Presentation of the Top Abstracts

Thursday, May 13, 3:30-5:15 p.m. (ET)

127. Base Editing Rescues Sickle Cell Disease in Human Hematopoietic Stem Cells and in Mice

Jonathan Yen, Ph.D., St. Jude Children’s Research Hospital

128. Safety and Efficacy Results with a Single Dose of Autologous CRISPR-Cas9-Modified CD34+ Hematopoietic Stem and Progenitor Cells (HSPCs) in Transfusion-Dependent β-Thalassemia (TDT) and Sickle Cell Disease (SCD)

Tony W. Ho, M.D., CRISPR Therapeutics

129. Immunostimulatory Bacterial Antigen-Armed Oncolytic Measles Virotherapy Significantly Increases the Potency of Anti-PD1 Checkpoint Therapy

Eleni Panagioti, Ph.D., Mayo Clinic

130. In-Vivo Engineered B Cells Retain Memory and Secrete High Titers of Anti-HIV Antibodies in Mice

Alessio David Nahmad, M.Sc., Tel Aviv University

Clinical Trials Spotlight Symposium

Friday, May 14, 10-11:45 a.m. (ET)

194. Systemic AAV Delivery Activates the Classical Complement Pathway Leading to Thrombotic Microangiopathy

Stephanie Salabarria, BH.Sc., University of Florida

195. Activity of Banked (Off-the-Shelf) CD30. CAR-Modified Epstein-Barr Virus-Specific T Cells in Patients with CD30-Positive Lymphoma

David Quach, Ph.D.

196. Updated Results From HGB-206 LentiGlobin for Sickle Cell Disease Gene Therapy Study: Group C Data and Group A AML Case Investigation

John Tisdale, M.D., National Institutes of Health

197. ADVM-022 Intravitreal Gene Therapy for Neovascular AM.D. - Results From the Phase 1 OPTIC Study

Szilárd Kiss, M.D., Weill Cornell Medicine

198. Natural Killer T Cells Expressing a GD2-CAR and IL-15 Are Safe and Can Induce Complete Remission in Children with Relapsed Neuroblastoma - A First-in-Human, Phase 1 Trial

Andras Heczey, M.D., Baylor College of Medicine

199. Long Term Follow Up for the Development of Subsequent Malignancies in Patients Treated With Genetically Modified Immune Effectors

David Steffin, M.D., Baylor College of Medicine

200. Updated Results of Transpher A, a Multicenter, Single-Dose, Phase 1/2 Clinical Trial of ABO-102 Gene Therapy for Sanfilippo Syndrome Type A (Mucopolysaccharidosis IIIA)

Kevin Flanigan, M.D., Nationwide Children’s Hospital

Related Articles

Annual Meeting

Global Speakers Address Developing Gene Therapies in Low- and Middle-Income Countries

Martín Bonamino, Ph.D. - June 03, 2021
Annual Meeting

Q&A with Bruce Pyenson

Francesca Cook, MPH - June 03, 2021
Annual Meeting

COVID-19 Vaccines to the Rescue

Edith Pfister, Ph.D. - May 28, 2021
Annual Meeting

Gene Therapy Progress: Challenges and Opportunities

Emily Walsh Martin, Ph.D. - May 26, 2021